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ABSTRACT
Deregulated expression of the MET receptor tyrosine kinase has been reported 
in up to 50% of patients with hepatocellular carcinoma, the most abundant form 
of liver cancers, and is associated with decreased survival. Consequently, MET is 
considered as a molecular target in this malignancy, whose progression is highly 
dependent on extensive angiogenesis. Here we studied the impact of MET small 
molecule inhibitors on angiogenesis-associated parameters and growth of xenograft 
liver models consisting of cells expressing MET-mutated variants M1268T and 
Y1248H, which exhibit constitutive kinase activity. We demonstrate that MET 
mutations expression is associated with significantly increased production of vascular 
endothelial growth factor, which is blocked by MET targeting only in cells expressing 
the M1268T inhibitor-sensitive but not in the Y1248H inhibitor-resistant variant. 
Decrease in vascular endothelial growth factor production is also associated with 
reduction of tyrosine phopshorylation of the vascular endothelial growth factor 
receptor 2 expressed on primary liver sinusoidal endothelial cells and with inhibition 
of vessel formation. Furthermore, MET inhibition demonstrated an efficient anti-tumor 
activity and considerable reduction in microvessel density only against the M1268T-
derived intrahepatic tumors. Collectively, our data support the role of targeting MET-
associated angiogenesis as a major biological determinant for liver tumor growth 
control. 
INTRODUCTION
Liver cancers, and in particular the most prevalent 
form of these tumors, hepatocellular carcinoma (HCC), are 
aggressive, chemotherapy-resistant human malignancies, 
which exhibit an increasing annual incidence and are 
associated with poor prognosis [1, 2]. In that respect, 
liver tumors constitute the sixth most common human 
malignancy and the third most common cause of cancer-
related mortality worldwide [3]. One of the most important 
reasons for the high mortality rate of patients with liver 
tumors is the absence of effective treatment options, 
especially in patients with advanced stages. Currently, the 
multi-kinase inhibitor sorafenib [4], which is believed to 
exert its major antitumor activity primarily by blocking 
the pro-angiogenic activity of vascular endothelial 
growth factor (VEGF) receptors 2 and 3 (VEGFR2 and 
VEGFR3), is the only approved treatment for advanced 
HCC and provides a median overall survival of 10.7 
months in previously untreated patients [5-7]. Apart of 
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primary tumors and due to being perfused by both arterial 
and venous blood, the liver often provides a unique 
microenvironment also to metastatic lesions of tumors of 
distinct histotypes [8].
Aberrant activation of the hepatocyte growth 
factor (HGF) receptor tyrosine kinase MET, mostly due 
to overexpression of the MET gene, is a common event 
in numerous types of human cancers and is frequently 
associated with poor prognosis [9]. In HCC, MET 
overexpression has been reported in 20-48% of tumor 
samples compared to peritumoral normal tissue [10-
15] and was further correlated with clinicopathological 
features of these tumors such as presence of multiple 
nodular tumors and association with high proliferative 
index [10, 16, 17]. In addition, patients with MET 
overexpression usually have a significantly shorter 5-year 
survival than patients with low MET expression after a 
curative surgical resection [11, 17, 18].
On the basis of the critical role that MET 
signaling plays in human cancer, various small 
molecule tyrosine kinase inhibitors (TKIs) that block 
the tyrosine phosphorylation of the catalytic domain 
of the receptor with subsequent arrest of downstream 
signal propagation are currently under clinical trials [19, 
20]. Most of the specific and non-specific MET TKIs 
function via competitively antagonizing occupancy 
of the intracellular ATP-binding site to prevent kinase 
domain phosphorylation. Few exceptions, such as 
ARQ197/tivantinib, bind to a region of MET outside of 
the ATP binding site and impair kinase activation through 
presumably conformational changes in a non-ATP 
competitive manner [21].
Apart of being directly correlated with definite 
tumor characteristics such as deregulated mitogenesis, 
motogenesis and resistance to apoptosis, various studies 
over recent years have highlighted the link between 
MET signaling and the formation of new blood vessels. 
An important work in this category by Zhang et al has 
substantially contributed to the understanding of the 
mechanisms that underlie MET-dependent tumor-
associated angiogenesis by showing that MET signaling 
directly up-regulates transcriptional activation of the 
VEGF gene and in parallel down-regulates the expression 
of thrombospondin-1, an angiogenesis suppressing factor 
[22]. In the context of tumor progression for example, 
Garcia et al reported in 2007 that MET overexpression 
in breast carcinomas correlates not only with shorter 
survival, but also with tumor neoangiogenesis [23]. 
With respect to the impact of MET inhibition on tumor-
associated vascularization, Puri et al were the first to show 
that growth attenuation of lung tumor xenografts in mice 
model by the MET small molecule TKI PHA665752 was 
associated with reduced blood vessels formation [24]. 
Similarly, Zou et al demonstrated that crizotinib, a non-
specific MET TKI, which is currently in phase III clinical 
trial for the treatment of non-small cell lung cancer, 
was able to inhibit in vitro tubulogenesis of primary 
endothelial cells [25]. As potential interplay between 
aberrant MET signaling and angiogenesis in HCC, a study 
by Kaposi-Novak reported a MET aberrant expression-
related transcriptional signature in a group of HCCs that 
were characterized by higher rate of vascular invasion and 
increased microvessel density [26], emphasizing therefore 
the potential role of MET-related angiogenesis in the 
pathogenesis of these tumors.
Taking into consideration the important emerging 
role of MET-dependent signaling in liver cancer 
pathogenesis with particular emphasis on MET-associated 
tumor vascularization, we investigated in the current 
study the potential of the MET TKIs to control growth 
and angiogenesis in models of MET-driven liver tumors, 
which consist of isogenic cell lines that ectopically express 
MET mutated variants that differ exclusively by their 
responsiveness to MET targeting.
RESULTS
M1268T and Y1248H MET-mutated variants 
display different sensitivities towards PHA665752
The prime interest of the current study was to 
evaluate in vitro as well as in an orthotopic liver tumor 
model the potential of two MET small molecules 
inhibitors, SU11274 and PHA665752 to interfere with 
tumor-associated angiogenesis. To that end we used 
isogenic NIH3T3 mouse fibroblast cells expressing 
the activating MET-mutated variants M1268T and 
Y1248H, which display in vitro sensitivity and resistance 
respectively towards SU11274 [27]. As suggested in 
Figure 1A (left panel), cells with the M1268T activating 
point mutation showed a dose-dependent decrease in 
MET phosphorylation upon PHA665752-treatment, 
similarly to the previously described effect of SU11274 
[27]. In contrary, no change in MET phosphorylated status 
was observed in Y1248H cells treated with increased 
concentrations of PHA665752 (Figure 1A, right panel). 
This indicates analogous inhibitory potential of SU11274 
and PHA665752.
Impact of MET inhibition on production of VEGF
In the last years, it has been reported that one of 
the biologic activities exerted by HGF on tumor cells is 
up-regulating the expression of the pro-angiogenic factor 
VEGF [28, 29]. In this section, we aimed to investigate 
whether the same is also valid for constitutively active 
oncogenic variants of MET and whether blocking of MET 
interferes with the production of VEGF by these cells. 
Initially, the impact of MET inhibition on VEGF mRNA 
levels has been investigated in NIH3T3 MET M1268T 
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and Y1248H cells via RT-PCR analysis. As Figure 1B 
indicates, both PHA665752 and SU11274 significantly 
reduced VEGF mRNA levels only in the M1268T variant 
cells with no apparent impact on cells expressing the 
Y1248H MET inhibition-resistant variant. We further 
incubated parental as well as NIH3T3 cell lines expressing 
MET M1268T and Y1248H activating mutations in 
presence or absence of the MET inhibitors SU11274 and 
PHA665752 for 24 hours. The levels of VEGF that were 
secreted by the cells were then measured in collected 
medium by ELISA. To exclude an effect due to different 
cell numbers caused by growth arrest impact of the MET 
inhibitors, the cells were counted when the media was 
collected and the VEGF amount was normalized to the 
cell counts.
Interestingly, we found that ectopic expression of 
MET in NIH3T3 was accompanied by a considerable 
increase in the production of VEGF of approximately 
3-fold compared to parental cells, confirming the previous 
observations of MET-dependent VEGF transcriptional 
upregulation [22]. Furthermore, while the MET inhibitor 
PHA665752 had no effect either on the production of 
VEGF in the drug-resistant cells expressing MET Y1248H 
variant or in the parental NIH3T3 cell line, the production 
of VEGF was significantly reduced upon PHA665752 
as well as SU11274 treatments in the cells carrying the 
inhibitor-sensitive MET mutation M1268T (Figure 1C 
and data not shown). In this case, the inhibition of MET-
dependent transcription of VEGF led to a significant, 
2,9-fold reduction of VEGF levels in culture medium 
(p<0.05).
In vitro pro-angiogenic effects of conditioned 
media from MET-driven tumor cells are 
diminished upon MET inhibition 
We further aimed to translate the findings from 
the previous section and to investigate the impact of the 
Figure 1: Impact of MET inhibition on VEGF signaling A. Effect of PHA665752 treatment (0-300nM for 16 hrs) on phosphorylation 
(Tyr1234/1235) of MET in NIH3T3 cells expressing the MET M1268T (left) and the MET Y1248H (right) mutation. B. VEGF mRNA 
levels in NIH3T3 MET M1268T and Y1248H following MET targeting by PHA665752 (50nM for 24 hrs) or SU11274 (2µM for 24 hrs) 
(***, p<0.0005). C. Effect of MET inhibition (METi; 50nM PHA665752 for 24 hrs) on MET-dependent production of VEGF (*, p<0.05). 
D. Impact of rhVEGF (upper panel), conditioned media collected from NIH3T3 MET M1268T cells (middle panel) and conditioned media 
collected from NIH3T3 MET Y1248H cells (lower panel) on VEGFR2 phosphorylation in LSECs (METi – PHA665752-treated cells, 
Undil. – undiluted medium, 1:2, 1:3, 1:9 – 2, 3 or 9 times diluted conditioned media).
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MET-dependent VEGF levels modification on biological 
endpoints. We tested the potential of conditioned media 
from PHA665752-treated and untreated M1268T and 
Y1248H cells to induce the phosphorylation of VEGF 
receptor type 2 (VEGFR2) on the surface of endothelial 
cells by Western Blot. Liver sinusoidal endothelial cells 
(LSECs) were stimulated with various dilutions of VEGF-
containing conditioned media. As positive control for 
this system, the impact of human recombinant VEGF 
(rhVEGF) on VEGFR2 phosphorylation in LSECs was 
tested (Figure 1D, upper panel). As shown in Figure 
1D, middle panel, we observed a remarkable decrease 
in VEGFR2 phosphorylation in the cells stimulated by 
media collected from PHA665752-treated, inhibitor-
sensitive MET mutants compared to media from control 
cells. On contrary, there was no difference in VEGFR2 
phosphorylation status of LSECs using media from treated 
and untreated Y1248H cells (Figure 1D, lower panel).
Further, the angiogenic effect of the culture media 
from treated or untreated NIH3T3 M1268T and Y1248H 
cells was assessed using the rat aortic ring assay. Dissected 
aortas of Wistar rats were placed onto matrigel which 
allows the sprouting of capillaries. As shown in Figure 2, 
the sprouting of vessels was completely abolished when 
rat aortic rings were incubated with medium coming from 
M1268T cells treated with MET inhibitors, compared to 
incubation with the medium of untreated M1268T cells. In 
contrast, this effect was not observed with media obtained 
from treated, inhibitor-resistant Y1248H cells.
PHA665752-mediated reduction of the size 
and the associated microvessel density of MET 
M1268T tumors in an orthotopic liver tumor 
model
To investigate whether the effects observed in 
vitro are of in vivo significance, NIH3T3 MET M1268T 
or Y1248H cells were injected subcapsularly into the 
liver of SCID mice. One week after injection, mice were 
randomized for PHA665752 (25mg/kg/day i.p.) or vehicle 
treatment. After seven days of treatment, tissues were 
harvested and tumor sizes and weights measured.
As aforementioned, PHA665752 acts by inhibition 
of the MET receptor tyrosine kinase activity and 
subsequently of its downstream signaling. To confirm 
that the effects observed on tumor xenografts were indeed 
mediated by PHA665752, we studied the phosphorylation 
status of MET in harvested tumors by Western blot 
analysis. In M1268T tumors, the phosphorylation of 
MET was significantly decreased (down to 50% of the 
non-treated samples, p<0.05) when the animals were 
receiving PHA665752 compared to vehicle-treated mice. 
By contrast, the treatment with PHA665752 reduced the 
phosphorylation of MET in Y1248H tumors only by 10% 
(Figure 3, p>0.05).
The size of PHA665752-sensitive M1268T tumors 
was significantly reduced in the animals treated with 
the MET inhibitor, compared to vehicle-treated mice 
(Figure 4A and 4B). In contrast, the treatment with 
PHA665752 had no effect on the size of the Y1248H 
Figure 2: In vitro angiogenesis studied by the rat aortic 
ring assay. A. Representative pictures of rings incubated 
with conditioned medium from NIH3T3 MET M1268T (left), 
NIH3T3 MET Y1248H (middle) cells or medium only (right) 
incubated with MET inhibitor (METi; SU11274). B. Vessels 
quantification. The vessel number was reduced after addition 
of medium from NIH3T3 MET M1268T cells treated with 
SU11274 (2µM) compared to medium from untreated cells 
(N=3; *, p<0.05). Exposure to medium obtained from the MET-
inhibitor treated NIH3T3 MET Y1248H cells slightly increased 
the number of vessels compared to medium from untreated cells.
Figure 3: Effect of METi on the phosphorylation status 
of NIH3T3 MET M1268T and Y1248H liver tumors. 
A. Western blot showing the phosphorylation status and the 
expression levels of MET in control and in PHA665752-treated 
(METi) NIH3T3 MET M1268T (left) and Y1248H (right) 
liver tumors. -, vehicle-treated liver tumors; +, PHA665752-
treated (METi) liver tumors. B. Quantification of pMET/MET 
expression normalized to β actin (N=5; *, p<0.05).
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liver tumors (Figure 4A and 4B). Specifically, M1268T 
tumors measured 604±207 mm3 in untreated mice and 
125±37 mm3 in PHA665752-treated mice (p<0.05) while 
Y1248H tumors measured respectively 178±116 mm3 and 
346±227 mm3 (p>0.05). Comparing tumor weights, very 
similar effect of reduction upon PHA665752 treatment 
was observed in the case of M1268T sensitive liver 
tumors (0.7±0.2g in untreated animals vs. 0.2±0.01g in 
animals treated by the MET inhibitor (p<0.05); Figure 
4C). Similarly to tumor size, there was a slight but not 
significant increase in the weight of Y1248H tumors upon 
PHA335752 treatment (0.3±0.2g vs. 0.4±0.3g; Figure 4C).
To assess the impact of MET inhibition on tumor 
angiogenesis, we evaluated the state of blood vessels in 
the tumor sections by immunohistochemical staining using 
an antibody against the endothelial cell surface marker 
CD31 (Figure 5A). Differences in CD31 staining upon 
MET inhibition were evaluated by assessing the mean 
area of CD31 positive zone and the mean vessels fiber 
length. The results shown in Figure 5B demonstrate that 
the mean area of CD31 positive signal was significantly 
reduced by 22% following PHA665752 administration in 
the MET inhibition-sensitive M1268T tumors whereas the 
drug had no corresponding effect in the resistant Y1248H 
tumors. A statistically significant reduction of 12% in the 
mean of vessels fibers length was also observed in the 
drug-sensitive M1268T tumors (p<0.05), with no parallel 
decrease in Y1248H-associated tumors (Figure 5C).
DISCUSSION
Liver cancers and in particular HCCs are 
hypervascularized tumors [30], a feature that highlights 
their particular potential sensitivity towards antiangiogenic 
targeting treatments. Indeed, this biologic rationale along 
with improvement of survival of patients with advanced 
HCC [6, 7] underlies the clinical application of the 
angiogenesis inhibitor sorafenib for the treatment of these 
malignant disorders. However, despite initial responses 
to sorafenib, potential escape mechanisms are probably 
responsible for disease relapses in most of the patients 
[31]. Another evidence for the benefit for interference 
with tumor-associated angiogenesis in liver cancers is 
provided by data from clinical and pre-clinical studies 
with mTOR inhibitors such as everolimus and sirolimus. 
mTOR inhibitors are believed to exert their antiangiogenic 
effects largely through regulation of VEGF expression 
and translation of other proteins involved in angiogenesis 
[32, 33]. In that respect, administration of everolimus in 
patients with advanced HCC has led to a median progress-
free survival of 3.8 months with a disease control rate of 
44% in phase I/II tests [34]. Moreover, administration of 
the anti-VEGF receptor 2 antibody ramucirumab in second 
line after sorafenib demonstrated a benefit in a subgroup 
of patients with HCC. Nevertheless, the current data that 
emerge from experiences with sorafenib strongly justify 
the identification of additional targeting approaches that 
exhibit among other effects also antivascularization 
properties, for the handling of liver malignancies.
Figure 4: Impact of METi treatment on the size and weight of liver tumors formed by NIH3T3 MET M1268T and 
Y1248H cells. A. Representative pictures of vehicle-(CONTROL) or PHA665752-treated (METi; 25 mg/kg/day) NIH3T3 MET M1268T 
(left) and Y1248H (right) liver tumor B. Quantification of tumor sizes (N=3; *, p<0.05), C. Quantification of tumor weights (N=3; p<0.05).
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In agreement with the role that aberrant biologic 
activity of the MET/HGF axis may play a role in the 
pathogenesis of liver tumors, there is a concomitant 
increase in the interest in MET as a molecular target in 
these malignancies [35]. Indeed, emerging pre-clinical 
data support the potential of MET as a clinical target 
in liver tumors. For example, it was recently described 
by Inagaki et al that the prototypic MET TKI SU11274, 
which was used also in the current study, suppressed 
HCC cell growth by inhibiting the activation of the 
receptor [36]. In this study, it was demonstrated that 
SU11274 suppressed the growth of HepG2, HuH7, and 
HLE hepatoma cells with IC50 values of 6–8 µmol/L in 
vitro. Expression of phosphorylated MET and of MET-
dependent phosphorylated ERK gradually decreased in 
a dose-dependent manner with SU11274. Concerning 
clinical evaluations, the most advanced compound in 
this category at present is tivantinib/ARQ197, an oral 
MET small molecule, which was identified as the first 
non-ATP competitor MET TKI [21]. Even though the 
exact mechanisms by which tivantinib exerts its activity 
have been questioned recently [37, 38], suggesting that 
in addition to MET inhibition, this TKI exhibits also 
a tubulin-associated cytotoxic activity, other studies 
indeed furnished data confirming the tivantinib anti-
MET targeting capacity [39-41]. Importantly, matched 
tumor samples from patients before and after treatment 
with tivantinib demonstrate MET inhibition [42]. Recent 
results of a phase II study suggest that tivantinib may be 
beneficial for patients with MET-positive HCC who have 
failed or show sorafenib-intolerance [43]. Another MET 
TKI that is evaluated in preclinical models of HCC is XL-
880/foretinib [44].
Despite the role of MET signaling in tumor 
angiogenesis [24, 25, 45] and the possible therapeutic 
benefit of targeting MET aberrant expression in liver 
tumors, the impact of MET inhibition on liver cancer-
associated angiogenesis has not been yet adequately 
reported. Consequently, in the current study we aimed to 
investigate the impact of aberrant MET activity targeting 
on pro-angiogenic activities in MET-driven tumor cells 
and in a liver xenograft model. In order to attribute directly 
the MET-dependent pro-angiogenic activities and in order 
to exclude off-target activities, we have chosen to use 
NIH3T3 cells that ectopically express constitutive active 
MET variants, which display sensitivity or resistance 
towards the MET TKIs SU11274 and PHA665752. 
The first interesting finding in the current report is that 
oncogenic MET activity is sufficient to induce production 
of VEGF, as indicated by the nearly 3-fold increase in 
VEGF in conditioned media of cells expressing the MET 
mutated variants as compared to parental cells. This 
Figure 5: Impact of METi on the microvessel density in NIH3T3 MET M1268T and Y1248H liver tumor sections. A. 
Representative pictures of CD31 immunostaining of vehicle-(CONTROL) or PHA665752-treated (METi; 25 mg/kg/day) NIH3T3 MET 
M1268T (left) and Y1248H (right) liver tumor sections. B. Quantification of CD31 mean area of positive signal per section (N=7; *, 
p<0.05), C. Quantification of mean fiber length (N=7; *p<0.05).
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finding matches well with the original study by Zhang et 
al. who were the first to demonstrate an HGF-dependent 
increase in VEGF expression in leiomyosarcoma and 
breast cancer cell lines [22]. Our data concerning 
the impact of MET inhibition on reduction of VEGF 
production by the MET M1268T cells are in accordance 
with the study by Puri et al who found a considerable 
reduction in VEGF expression in lung cancer xenografts in 
mice following treatment with the MET TKI PHA665752 
[24]. Similar results were shown by Zou et al who reported 
reduction of the pro-angiogenic factors VEGF and IL-8 
in response to the MET small molecule PF-02341066 in 
tumor models derived from GTL-16 and U-87 cell [25]. 
In vivo, we could demonstrate that MET inhibition was 
bound to a decrease in the size and in the vascularization 
of tumor in a murine liver xenograft model. Altogether, 
the data of this manuscript provide further support for the 
importance of blocking of MET-associated angiogenesis in 
a hypervascularized microenvironment as that of the liver 
for efficient tumor growth control.
MATERIALS AND METHODS
Cell culture
Parental NIH3T3 cells as well as NIH3T3 cell 
lines, which stably express the MET-mutated variants 
M1268T and Y1248H were obtained from Dr. Laura 
Schmidt (National Cancer Institute NCI, Fredrick, MD, 
USA) and maintained in DMEM (GIBCO, Invitrogen 
Corp.) supplemented with 10% FCS (Sigma), antibiotic-
antimycotic (penicillin 100U/ml, streptomycin sulfate 
100U/ml, amphotericin B as Fungizone 0.25ug/ml 
GIBCO, Invitrogen Corp.). In addition, medium for MET-
mutated cells contained 0,5mg/ml Geneticin/G-418 sulfate 
(GIBCO, Invitrogen Corp.).
Primary liver sinusoidal endothelial cells (LSECs) 
were kindly provided by the laboratory of Dr. Deborah 
Stroka (Department of Clinical Research, University of 
Berne, Switzerland) and were cultured on plastic coated 
with collagen in Human Endothelial-SFM Basal Growth 
Medium (GIBCO, Invitrogen Corp.) supplemented with 
GPS, 20% Human Serum, HGF (final concentration (f.c.) 
of 10ng/ml) and VEGF (f.c. 2ng/ml).
Small molecules
Small molecules SU11274 [(3Z)-N-(3-
chlorophenyl)-3-({3,5-dimethyl-4-[(4- methylpiperazin-
1-yl)carbonyl]-1H pyrrol-2-yl}methylene)-Nmethyl-
2-oxoindoline-5-sulfonamide] as well as PHA665752 
(3Z)-5-[(2,6-dichlorobenzyl)sulfonyl]-3-[(3,5-dimethyl-4-
([(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl)-
1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one 
were obtained from SUGEN, Inc. ((Pfizer) South San 
Francisco, CA, USA).
Stock dilutions of the drugs (10mM) were prepared 
in dimethylsulfoxide (DMSO) and stored in solution at 
-20°C. Final dilutions for cellular assays were prepared 
immediately before use in the corresponding media.
Antibodies
Rabbit polyclonal anti-phospho-MET 
(Tyr1234/1235) and rabbit monoclonal anti-phospho-
VEGFR2 (Tyr1175) and anti-VEGFR2 antibodies were 
obtained from Cell Signaling (Cell Signaling Technology, 
Inc., Beverly, MA, USA). Rabbit polyclonal anti-MET 
(SP260) antibody was purchased from Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA. Rabbit 
polyclonal anti-beta-actin antibody was obtained from 
Sigma (Fluka, Buchs, Switzerland). Rat monoclonal anti-
mouse CD31 (clone JC/70A) antibody was purchased 
from Dako, Glostrup, Denmark.
Conditioned media
NIH3T3 cells expressing the MET-mutated variants 
M1268T and Y1248H were plated and incubated in the 
presence or absence of MET small molecule inhibitors 
PHA665752 (100 and 200nM) and SU11274 (2µM). 
Twenty-four hours later, the conditioned media of the 
cells were collected, centrifuged and used for further 
experiments. 
Determination of VEGF concentration in 
conditioned media
The concentration of VEGF in the culture media 
was measured according to the instructions of the 
ELISA Mouse VEGF kit (Mouse VEGF Quantikine, 
R&D Systems Europe, Ltd., Abingdon, UK) in flat 
bottom transparent polystyrol microtiterplates. The 
reaction was stopped with 2N H2SO4 and hydrogen 
peroxide in a buffered solution together with 3,3’,5,5’ 
tetramethylbenzidine in organic solvent (BD PharMingen, 
Heidelberg, Germany) were used as substrate solutions. 
The absorbance at 450 nm (with 570 nm correction) was 
read using InfiniteTM 200 Tecan (Tecan Group Ltd.) and 
the concentration of VEGF was determined according to 
standard curves. The amount of VEGF produced by the 
cells was normalized to the count of cells following the 
collection of the media.
RNA isolation and Real-time PCR
Total RNA was extracted from cultured cells using 
Trizol reagent following the manufacturer’s instructions 
Genes & Cancer324www.impactjournals.com/Genes&Cancer
(Roche). Reverse transcription of mRNA was performed 
using the Omniscript RT Kit (Qiagen). Quantitative PCR 
of VEGF-A was assessed using a 7900HT fast Real-time 
PCR system (Applied Biosystems) using a TaqMan assay 
(Applied Biosystems). The mean CT was determined from 
triplicate experiments, mRNA levels were normalized to 
the level obtained for TATA-box-binding protein (TBP). 
Changes in expression were determined by calculations 
of ΔΔCT.
Cell stimulation and immunoblot analysis
After reaching approximately 60% confluency, 
LSECs were incubated in starvation medium (0.1% 
HCS, without growth factors) for 16 hours and then 
stimulated for 10 minutes at 37°C with various dilutions 
of conditioned media obtained from treated as well as 
untreated NIH3T3 MET- mutated cells. LSECs were then 
lysed by sonication and lysates were loaded together with 
SDS loading buffer (Bio-Rad Laboratories, Inc.) onto 7% 
SDS-polyacrylamide gel electrophoresis. 
NIH3T3 MET-mutated cells were treated for 16 
hours with various concentrations of PHA665752 and 
lysed in lysis buffer (1% Triton X-100, 0.5% Nonident 
NP-40, 1mM EGTA, 1mM EDTA, 150mM NaCl, 10mM 
Tris-HCl, 1mM Na3VO4, 10mM NaF, 1mM ZnCl2, 50mM 
Na2MoO4, 1.4mg/ml aprotinin, 35ng/ml PMSF, a cocktail 
of proteases inhibitor (Complete Mini, Roche)).
Tissues were homogenized in 0.25 M sucrose 
(Polytron; Janke&Kunken KG IGA Werk, Staufen, 
Germany).
Protein concentration was determined by using 
the BioRad protein quantification reagent (Bio-Rad 
Laboratories, Inc.). Fifty micrograms of total protein 
were resolved by SDS-PAGE on a 7% gel and transferred 
onto a PVDF membrane. After blocking and incubating 
with specific primary antibodies, membranes were 
incubated with horseradish peroxidase-linked secondary 
antibody (Amersham Pharmacia Biotech, Piscataway, NJ). 
Detection of secondary antibodies was performed using 
the ECL kit (Amersham) and autoradiography.
Aortic ring assay
Thoracic aortas excised from 8- to 12-week-old 
ACI rats (range 180-230 g) were cut into 1-mm-long 
cross-sections. Rings were placed on matrigel-coated 
wells with F12-K medium (Gibco, Basel, Switzerland) 
with 10% fetal bovine serum (Sigma-Aldrich Chemie 
GmBH, Munich, Germany), penicillin, streptomycin and 
supplemented with 10ng/ml epidermal growth factor and 
25µg/ml heparin. Conditioned media from SU11274-
treated as well as untreated NIH3T3 cells were added. 
After 5 days, rings were fixed and stained using a Diff-
Quick solution II staining protocol (Diff-Quick Stain 
Set; Baxter-Dade AG Düdingen, Switzerland). Vascular 
outgrowth was quantified by counting all sprouts from 
one ring. All assays were performed in triplicate and each 
experiment was repeated three times.
In vivo studies
NIH3T3 MET M1268T or Y1248H cells (2,5x105 
cells/animal) were injected subcapsularly into the liver of 
12-18 weeks old SCID mice (Harlan, Indianapolis, USA). 
One week after implantation, mice were randomized for 
PHA665752 (25mg/kg/day i.p.) or vehicle treatment. After 
seven days of treatment, tissues were harvested and tumor 
sizes and weights measured. Animals received humane 
care in accordance with the regulations for laboratory 
animals and the experiments were performed following 
protocols approved by the animal use committee of the 
Canton of Berne, Switzerland.
Microvessel density
The vascularization of tumors was quantified by 
CD31 immunohistochemistry. The microvessel density 
(mean area and mean fiber length) was determined blindly 
as described by Weidner and Folkman [46].
Statistics
If not stated differently, statistics results are 
presented as mean +/- standard deviation. Comparisons 
were performed with a non-parametric Mann-Whitney test 
and Student T test.
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